Kangleweishi’s nine-valent HPV vaccine research and development has made significant progress
March 4, 2025
Source: drugdu
139
On the evening of February 28, Kangleweishi issued an announcement stating that on the same day, the independent data monitoring committee (IDMC) of the domestic phase III protective efficacy clinical trial of the company's independently developed recombinant nine-valent human papillomavirus (6/11/16/18/31/33/45/52/58) vaccine (Escherichia coli) (female indication) has completed the first analysis unblinding, primary efficacy indicators and safety evaluation, and the company has received the IDMC's recommendation letter based on the first analysis results.
The company stated that the independent data monitoring committee (IDMC) confirmed that the efficacy results met the first analysis statistical criteria preset in the protocol. The first analysis results of the company's nine-valent HPV vaccine (female indication) domestic phase III protective efficacy clinical trial were in line with expectations, marking a major progress in the clinical research of the nine-valent HPV vaccine.
The company said the development is not expected to have a material impact on its financial condition and operating results in the near term.
https://finance.eastmoney.com/a/202503023333966557.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Zhengda Tianqing targets 9.2 billion yuan drug September 18, 2025
- Announcement on the Holding Subsidiary Obtaining Medical Device Registration Certificate September 18, 2025
- Plans to invest RMB 42.74 million in Wuhan Huajiyuan to advance clinical trials of the therapeutic antihypertensive vaccine (HJY-ATRQβ-001) project September 18, 2025
- Eli Lilly wins again! Oral weight loss drug outperforms oral sirolimus in head-to-head tria September 18, 2025
- Hengrui’s breakthrough hepatitis B therapy arrives September 17, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
